Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector

Bo Liang
Joan O. Ngwuta
Richard Herbert
Joanna Swerczek

Bo Liang;Joan Ngwuta;Richard Herbert;Joanna Swerczek;David Dorward;Emerito Amaro-Carambot;Natalie Mackow;Barbora Kabatova;Matthias Lingemann;Sonja Surman;Lijuan Yang;Man Chen;Syed Moin;Azad Kumar;Jason McLellan;Peter Kwong;Barney Graham;Anne Schaap-Nutt;Peter Collins;Shirin Munir


Human respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major pediatric respiratory pathogens that lack vaccines. A chimeric bovine/human PIV3 (rB/HPIV3) virus expressing the unmodified, wild-type (wt) RSV fusion (F) protein from an added gene was previously evaluated in seronegative children as a bivalent intranasal RSV/HPIV3 vaccine, and it was well tolerated but insufficiently immunogenic for RSV F. We recently showed that rB/HPIV3 expressing a partially stabi